In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Keith Ellison said he's reached a deal with Danish pharmaceutical company Novo Nordisk to keep the cost of insulin at $35 a ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Frozen’s Josh Gad shared insight into his weight loss journey after losing 40 pounds with the help of medication.

Anti-obesity drug Mounjaro is set rack up sales of nearly £22bn a year by 2030. But Trump's 'America First' policies mean Britons could soon be paying more for the 'King Kong' of weight-loss jabs ...

President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...